Previous 10 | Next 10 |
ChemoCentryx (CCXI) -49% after FDA panel split 9-9 on efficacy for Chemocentryx's vasculitis candidate avacopan and reports outcome of FDA’s expert panel meeting on avacopan.Orphazyme (ORPH) -28% after arimoclomol flunks late-stage amyotrophic lateral sclerosi...
Gainers: SemiLEDs (LEDS) +106%.Lexaria Bioscience (LEXX) +49%.Stealth BioTherapeutics (MITO) +38%.Liquidity Services (LQDT) +27%.Applied UV (AUVI) +25%.BioCryst Pharmaceuticals (BCRX) +21%.Avid Technology (AVID) +21%.Summit Wireless Technologies (WISA) +20%.WW International (WW) +20...
Gainers: Stealth BioTherapeutics (MITO) +45%, Biofrontera (BFRA) +18%, BioCryst Pharmaceuticals (BCRX) +15%, Orgenesis (ORGS) +12%, GT Biopharma (GTBP) +4%.Losers: Regional Health Properties (RHE) -24%, VYNE Therapeutics (VYNE) ...
3 Penny Stocks to Watch in May 2021 As May gets off to a bright start for penny stocks, which ones are investors watching? This is a tough question to answer simply. However, there are a few things that all penny stocks investors should consider. The first is speculation. Speculatio...
Clinical-stage biotechnology company, Stealth BioTherapeutics (MITO) presents new data from a post hoc analysis of the Phase 1 ReCLAIM study evaluating elamipretide in patients with non-central geographic atrophy (or GA) and high risk drusen associated with dry age-related macular degene...
Stealth BioTherapeutics (MITO) +58% after showcases data for Elamipretide.Luokung Technology Corp. (LKCO) +22% on announcing favorable ruling granting preliminary injunction.Nemaura Medical (NMRD) +23% on 200K sugarBEAT sensors order.American Shared Hospital Services (AMS) +28%...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, investors, and good morning. We’re getting ready for another busy day of trading here at InvestorPlace . That means we’re listing out the biggest pre-market stock movers for Wednesday to start t...
Stealth BioTherapeutics Showcases Data for Elamipretide in Dry Age-Related Macular Degeneration at the 2021 ARVO Annual Meeting PR Newswire BOSTON , May 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company fo...
Stealth BioTherapeutics Announces Poster Presentation at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting Presentation supports company's design of ReCLAIM-2, which is focused on earlier stages of geographic atrophy (GA) PR Newswire...
Stealth BioTherapeutics CEO to Give Keynote Presentation at Mitochondria-Targeted Drug Development Summit PR Newswire BOSTON , April 26, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discov...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp. Website:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...